Market Access Jazz and Lilly cancer drugs cleared for use by NHS PharmaphorumJazz's biliary tract cancer drug Ziihera and Lilly's Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance.Market AccessOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Jazz’s biliary tract cancer drug Ziihera and Lilly’s Jaypirca for chronic lymphocytic leukaemia have been backed for NHS use in new NICE guidance. Market AccessOncologyRead full story Post navigation Previous: The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain GroundNext: Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026
